ReviewBioconjugate chemistry2026
Peptide-Based PROTACs: Transitioning from Static Paradigm to a Dynamic Landscape within Targeted Protein Degradation.
Review in Bioconjugate chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Proteolysis-targeting chimeras (PROTACs) are becoming a powerful therapeutic strategy, enabling event-driven elimination of disease-causing proteins. While small-molecule PROTACs have advanced rapidly, their broader application is constrained by limited target scope, dependence on druggable binding pockets, and susceptibility to the hook effect. Peptide-based PROTACs (pPROTACs) have gained attention as a complementary platform, leveraging the specificity, modularity, and structural adaptability of conjugates to expand the range of degradable targets, including proteins traditionally considered undruggable. This review summarizes recent advances in classical pPROTAC design and conjugation strategies and highlights emerging nonclassic and deconstructive pPROTAC architectures that reassemble functional modules through supramolecular or genetic approaches. Further, bioPROTAC, as a protein-based degrader enabled by genetic encodability, is discussed. Together, these strategies position pPROTACs as an evolving class of targeted protein degradation agents that complement small-molecule approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.